Barclays PLC Decreases Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

Barclays PLC decreased its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 410,476 shares of the company’s stock after selling 7,500 shares during the quarter. Barclays PLC owned approximately 0.60% of COMPASS Pathways worth $2,586,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Green Alpha Advisors LLC acquired a new position in shares of COMPASS Pathways during the third quarter worth about $99,000. Y Intercept Hong Kong Ltd acquired a new position in COMPASS Pathways during the 3rd quarter worth approximately $131,000. Fore Capital LLC purchased a new stake in shares of COMPASS Pathways in the 2nd quarter valued at approximately $181,000. Point72 Asset Management L.P. acquired a new stake in shares of COMPASS Pathways in the 3rd quarter valued at $371,000. Finally, AdvisorShares Investments LLC lifted its position in shares of COMPASS Pathways by 13.5% during the 2nd quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock worth $362,000 after purchasing an additional 7,243 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Trading Down 0.5 %

CMPS opened at $4.03 on Wednesday. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 52 week low of $3.86 and a 52 week high of $12.75. The business’s 50 day moving average is $4.99 and its two-hundred day moving average is $6.18. The firm has a market cap of $275.74 million, a price-to-earnings ratio of -1.83 and a beta of 2.25.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter in the previous year, the company posted ($0.67) earnings per share. On average, research analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analysts Set New Price Targets

CMPS has been the topic of several recent analyst reports. HC Wainwright dropped their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Maxim Group cut their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Finally, Royal Bank of Canada cut their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $33.60.

Insider Transactions at COMPASS Pathways

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares of the company’s stock, valued at approximately $41,779,932.70. The trade was a 27.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.25% of the company’s stock.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.